雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效

Clinical Efficacy of Raltitrexed Combined with Docetaxel for Advanced Gastric Cacinoma

目的探讨雷替曲塞联合多西他赛治疗晚期胃癌的临床疗效及安全性。方法 90例晚期胃癌患者随机分为A、B组,A组45例采用雷替曲塞联合多西他赛化疗方案;B组45例采用多西他赛化疗方案。治疗2周期后,比较两组患者的疗效及不良反应。结果患者接受治疗后均可评价疗效。A组总有效率(53.33%)显著高于B组(31.11%),差异具有统计学意义;两组主要不良反应均为骨髓抑制、恶心呕吐、脱发、关节酸痛、外周神经炎、口腔黏膜炎等,且A组骨髓抑制、关节酸痛、转氨酶升高和贫血的发生率高于B组,但无显著差异;两组未见因不良反应延缓化疗的患者,且无化疗相关性死亡。结论雷替曲塞联合多西他赛方案治疗晚期胃癌疗效优于多西他赛,且不良反应较轻,值得临床推广使用。

Objective To explore clinical efficacy and safety of raltitrexed combined with docetaxel in the treatment of advanced gastric carcinoma. Methods Ninety patients with advanced gastric carcinoma were randomly divided into groups A and B. Group A(45 cases) was given the chemotherapy of raltitrexed combined with docetaxel, while group B(45 cases) given docetaxel alone chemotherapy. The therapeutic effects, toxic and side effects of 2 groups were compared after 2 cycles of treatments. Results The therapeutic effects of all patients after chemotherapy were evaluated. The total effective rate(53.33%) in group A was significantly higher than that of group B(31.11%), and the difference showed statistical significance. Toxic and side effects of 2 groups mainly included myelosuppression, nausea and vomiting, alopecia, joint pain, peripheral neuritis and oral mucositis, and the incidences of myelosuppression, joint pain, increased transaminase and anemia in group A were higher than those in group B, but there were no signifi cant difference. There were no patients whose chemotherapy was delayed due to toxic reactions, and no chemotherapy-related death. Conclusion The therapeutic effects of raltitrexed combined with docetaxel in the treatment of advanced gastric carcinoma are better than that of docetaxel alone, and its toxic and side effects are slight, so it is worthy of being popularized and applied in clinic.